首页|Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling
Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
维普
Fluoxetine(Prozac™)is the only antidepressant approved by the US Food and Drug Administration(FDA)for the treatment of major depressive disorder(MDD)in children.Despite its considerable efficacy as a selective serotonin reuptake inhibitor,the possible long-term effects of fluoxetine on brain development in children are poorly understood.In the current study,we aimed to delineate molecular mechanisms and protein biomarkers in the brains of juvenile rhesus macaques(Macaca mulatta)one year after the discontinuation of fluoxetine treatment using proteomic and phosphoproteomic profiling.We identified several differences in protein expression and phosphorylation in the dorsolateral prefrontal cortex(DLPFC)and cingulate cortex(CC)that correlated with impulsivity in animals,suggesting that the GABAergic synapse pathway may be affected by fluoxetine treatment.Biomarkers in combination with the identified pathways contribute to a better understanding of the mechanisms underlying the chronic effects of fluoxetine after discontinuation in children.
Major depressive disorderFluoxetineRhesus monkeysProteomicsGABAergic synapse
Yu Yan、Dong Ik Park、Anja Horn、Mari Golub、Christoph W.Turck
展开 >
Proteomics and Biomarkers,Max Planck Institute of Psychiatry,Munich 80804,Germany
Aarhus University,Department of Biomedicine,8000 Aarhus,Denmark
Ludwig-Maximilians-Universität,Chair of Vegetative Anatomy,Institute of Anatomy,Faculty of Medicine,Munich 80336,Germany
Department of Environmental Toxicology,University of California,Davis,CA 95616,USA
展开 >
Max Planck Society to C.W.T.and National Institutes of Health USDHHSMax Planck Society to C.W.T.and National Institutes of Health USDHHS
万方数据
维普
